Hemagglutinin polypeptides, and reagents and methods relating thereto

Patent metadata

Field	Value
Publication number	US-10226527-B2
Application number	US-201113253060-A
Country	US
Kind code	B2
Filing date	Oct 4, 2011
Priority date	Oct 4, 2010
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.

First claim

We claim:

1. A pharmaceutical composition comprising:
a polypeptide that is a H5 hemagglutinin (“HA”) polypeptide having an amino acid sequence, using positions based on the canonical H3 numbering system that:
i) differs from but shows at least 95% identity with that of a reference H5 HA selected from the group consisting of A/Vietnam/1203/04 (SEQ ID NO: 50), A/Egypt/2786-NAMRU3/06 (SEQ ID NO: 51), and A/chicken/Vietnam/NCVD-093/08 (SEQ ID NO: 69);
ii) has a deletion at one or more positions selected from the group consisting of: 128, 129, 130, 131, 132, 133, 134, 135, 136, and combinations thereof; and, except for the deletion,
iii) maintains conserved residues of HA Sequence Elements 1 and 2 as set forth in SEQ ID NO: 106 and SEQ ID NO: 118, respectively.

2. The pharmaceutical composition of claim 1 , wherein the H5 HA polypeptide competes with the reference H5 HA polypeptide for interaction with an umbrella topology glycan.

3. The pharmaceutical composition of claim 1 , wherein the H5 HA polypeptide amino acid sequence has a deletion of the amino acid residue at a position selected from 130, 131, 132, and 133.

4. The pharmaceutical composition of claim 2 , wherein the umbrella topology glycan comprises long α2-6 sialylated glycans.

5. The pharmaceutical composition of claim 4 , wherein the long α2-6 sialylated glycans are selected from the group consisting of Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3 GalNAcβ1-4GlcNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GalNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-3GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3Galβ1-4GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3 GalNAcβ1-4GlcNAcβ1-3Galβ1-3GalNAc, NeuAcα2-3Galβ1-3 GalNAcα2-6Neu5Ac, Neu5Acα2-6Galβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3 Galβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3GalNAcβ1-4GlcNAcβ1-3/6GalNAc, NeuAcα2-6Galβ1-4GalNAcβ1-6GlcNAcβ1-3 Galα2-3Neu5Ac, NeuAcα2-6Galβ1-4GalNAcβ1-3/6GlcNAcβ1-3/6Galα2-3/6Neu5Ac, Neu5Acα2-6Galβ1-3GalNAcβ1-4Galα1-3Galβ1-4Glc, Neu5Acα2-6Galβ1-3GalNAcβ1-3Galβ1-4Galβ1-4Glc, Neu5Acα2-6Galβ1-3GlcNAcβ1-3Galβ1-4Glc and Neu5Acα2-6Galβ1-4GlcNAcβ1-3 Galβ1-4Glc.

6. The pharmaceutical composition of claim 2 , wherein the H5 HA polypeptide binds to umbrella topology glycans with an affinity that is at least 50%, at least 70%, at B least 80%, at least 90% or at least 100% of that observed for a wild type HA that mediates infection of humans.

7. The pharmaceutical composition of claim 2 , wherein the H5 HA polypeptide binds to umbrella topology glycans with greater affinity than it binds to cone topology glycans.

8. The pharmaceutical composition of claim 2 , wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 2.

9. The pharmaceutical composition of claim 2 , wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 5.

10. The pharmaceutical composition of claim 2 , wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 10.

11. The pharmaceutical composition of claim 2 , wherein the interaction occurs between the H5 HA polypeptide and umbrella topology glycans on HA receptors found on human upper respiratory epithelial cells, the bronchus, trachea, or the deep lung.

12. The pharmaceutical composition of claim 1 , wherein the H5 HA polypeptide differs from the reference H5 HA polypeptide at one or more positions selected from the group consisting of 131, 132, 133, 137, 155, 159, 160, 193, 224, and 226.

Assignees

• Tharakaraman Kannan
• Viswanathan Karthik
• Raman Rahul
• Sasisekharan Ram
• Massachusetts Inst Technology

Inventors

• Tharakaraman Kannan
• Viswanathan Karthik
• Raman Rahul
• Sasisekharan Ram

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/12

  Viral antigens · CPC title